Loading clinical trials...
Loading clinical trials...
This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of diffuse cutaneous systemic sclerosis (SSc). Approx...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Corbus Pharmaceuticals Inc.
NCT06375005 · Diffuse Cutaneous Systemic Sclerosis
NCT06152172 · Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, and more
NCT05270668 · Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
NCT05626751 · Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
NCT04986605 · Diffuse Cutaneous Systemic Sclerosis
University of California San Diego
La Jolla, California
Pacific Arthritis Care Center
Los Angeles, California
UCLA
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions